Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced HER2+Breast Cancer × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9099 Triple Negative Breast Neoplasms 907 Neoplasms 518 Ovarian Neoplasms 486 Neoplasm Metastasis 457 Colorectal Neoplasms 411 Carcinoma, Non-Small-Cell Lung 410 Prostatic Neoplasms 384 Lung Neoplasms 381 Pancreatic Neoplasms 280 Melanoma 259 Stomach Neoplasms 258 Breast Neoplasms, Male 237 Motor Activity 229 Colonic Neoplasms 207 Head and Neck Neoplasms 195 Uterine Cervical Neoplasms 194 Endometrial Neoplasms 194 Carcinoma, Intraductal, Noninfiltrating 191 Carcinoma, Renal Cell 166 Squamous Cell Carcinoma of Head and Neck 159 Sarcoma 156 Brain Neoplasms 145 Urinary Bladder Neoplasms 141 Esophageal Neoplasms 136 Breast Carcinoma In Situ 136 Lymphedema 130 Fatigue 122 Carcinoma, Ovarian Epithelial 122 Small Cell Lung Carcinoma 111

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡